Navigation Links
Sunesis Pharmaceuticals Receives NASDAQ Notification
Date:4/17/2009

SOUTH SAN FRANCISCO, Calif., April 17 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated April 14, 2009, from the Listing Qualifications Department of The NASDAQ Stock Market notifying the Company that it does not comply with the $10.0 million minimum stockholders' equity requirement for continued listing on The NASDAQ Global Market set forth in NASDAQ Marketplace Rule 5450(b)(1)(A). NASDAQ's determination was based on a review of the Company's Annual Report on Form 10-K for the period ended December 31, 2008. At that time, the Company's stockholders' equity was reported at $6.5 million. Since that time, the Company announced an up to $43.5 million financing, of which the first $10.0 million was received on April 3, 2009 upon the issuance of shares of the Company's Series A preferred stock and warrants and the remainder of which may be issued by the Company, subject to approval by the Company's stockholders, upon the satisfaction of a certain clinical milestone and the Company's common stock trading above a specified floor price or upon approval by a majority of the investors in the private placement, among other conditions. While the Company does not anticipate that it will meet the $10.0 million of stockholders' equity continued listing requirement as of March 31, 2009 on a GAAP or pro-forma basis after giving effect to the $10.0 million private placement, the amount of the shortfall depends on the net proceeds from the initial closing of the private placement, the amount of the restructuring charge from the Company's reduction in force on March 31, 2009 and the application of GAAP to the terms of the newly issued securities, which the Company is in the process of analyzing.

As provided in the NASDAQ rules, the Company has the opportunity to submit to NASDAQ a specific plan and
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
2. Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
3. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
4. Sunesis to Present at Upcoming Conferences
5. Sunesis to Present at Upcoming Conferences
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
(Date:6/19/2013)... 18, 2013 A new look at ... and other trends will highlight technical sessions at ... fall. In its 33rd year, the three-day event is ... of key suppliers, approximately 100 technical presentations and numerous ... international society for optics and photonics , the meeting ...
(Date:6/19/2013)... Adding to their already extensive supply ... Simport’s Dropette® and Heathrow Scientific disposable plastic ... basic biology, chemistry and any type of liquid handling ... 35 years, Simport has been supplying the science community ... the Simport Dropette®. Simport’s Dropette® is a one-piece ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... RUTHERFORD, N.J. , Feb. 10 Cambrex Corporation (NYSE: ... December 31, 2009 . , Highlights , ... sales decreased 15.8% compared to fourth quarter 2008.  For the full year ... foreign currency. EBITDA was $9.4 million in the fourth ...
... , , ... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer,of alternative drug ... , Ph.D., was chosen to lecture at the Third,International Conference on ... Basel, Switzerland on February 11, 2010 . Dr. Kidron,will ...
... , PLANTATION, Fla. and ... Biotechnology Inc., a full service Contract Biomanufacturing Company ... agents, jointly announced today their collaborative agreement on ... customer projects in Nuclear Medicine involving Chelation, Bioconjugation ...
Cached Biology Technology:Cambrex Reports Fourth Quarter and Full Year 2009 Results 2Cambrex Reports Fourth Quarter and Full Year 2009 Results 3Cambrex Reports Fourth Quarter and Full Year 2009 Results 4Cambrex Reports Fourth Quarter and Full Year 2009 Results 5Cambrex Reports Fourth Quarter and Full Year 2009 Results 6Cambrex Reports Fourth Quarter and Full Year 2009 Results 7Cambrex Reports Fourth Quarter and Full Year 2009 Results 8Cambrex Reports Fourth Quarter and Full Year 2009 Results 9Cambrex Reports Fourth Quarter and Full Year 2009 Results 10Cambrex Reports Fourth Quarter and Full Year 2009 Results 11Cambrex Reports Fourth Quarter and Full Year 2009 Results 12Cambrex Reports Fourth Quarter and Full Year 2009 Results 13Cambrex Reports Fourth Quarter and Full Year 2009 Results 14Cambrex Reports Fourth Quarter and Full Year 2009 Results 15Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 2Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 3Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration 2
(Date:6/19/2013)... of Pittsburgh has developed antibacterial compounds, derived from ... potential treatments for drug-resistant bacterial infections and appear ... quite small, making them inexpensive and easy to ... 2013 issue of the journal Antimicrobial Agents ... probable applications will likely be the chronic bacterial ...
(Date:6/19/2013)... , June 19, 2013 MedNet ... in clinical study management systems, is pleased to announce ... be held June 23-27 in Boston ... MedNet, a recognized leader in cloud-based eClinical solutions, has ... will be showcasing iMedNet™ EDC , ...
(Date:6/19/2013)... is the most potent physiological anabolic agent for ... synthesis of lipids, protein and carbohydrates, and inhibiting ... It also plays a major role in stimulating ... is metabolized and removed from the blood following ... molecular mechanisms by which insulin regulates glucose uptake ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2
... and likely to die of - heart disease compared ... are to blame, according to a new University of Leicester ... Maciej Tomaszewski, New Blood Lecturer in Cardiovascular Medicine in the ... that this "male disadvantage" may be related to the sex-specific ...
... an agreement was reached by the Alliance for a ... sales restrictions on "competitive foods" such as soft drinks ... say limiting the availability of soft drinks at school ... elementary school children. In a study of more ...
... Tech have used skin cells to create artificial bones ... into other tissues such as tendons or ligaments. The ... softer tissue rather than the sudden shift of previously ... and allowing them to handle weight more successfully. The ...
Cached Biology News:Sex hormones link to heart risk 2Engineers create bone that blends into tendons 2
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
Biology Products: